Skip to main content
Premium Trial:

Request an Annual Quote

Patents Held by Benitec, Collaborator Allowed in US, South Korea, China


Benitec Biopharma said this week that the US Patent and Trademark Office has granted a patent from the company’s core Graham intellectual property portfolio.

Additionally, the company said it has received a South Korean patent related to its lead hepatitis C drug candidate TT-034, while a collaborator on its non-small cell lung cancer program has been issued a patent related to the use of RNAi to sensitize treatment-resistant lung cancer cells.

The US patent application, No. 20120135517, is entitled “Methods and Means for Obtaining Modified Phenotypes,” and claims DNA constructs targeting multiple genes with a broader range of length limitations on the sequence than in earlier patents, Benitec said. The constructs can also be used in a range of cells, including potentially stem cells.

The South Korean patent, which is owned by Benitec, is entitled “Multiple Promoter Expression Cassettes for Simultaneous Delivery of RNAi Agents,” the company noted.

The Chinese patent was issued to the University of New South Wales, and is entitled “Methods for Detecting and Modulating the Sensitivity of Tumor Cells to Anti-Mitotic Agents.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.